Reviparin sodium

Known as: reviparin-sodium 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2011
012319962011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Reviparin sodium (clivarine) is a second generation LMWH, developed with the aim of maximising the antithrombotic action while… (More)
Is this relevant?
2002
2002
BACKGROUND Oral anticoagulants and low-molecular-weight heparin are both recommended for venous thromboembolism prophylaxis after… (More)
Is this relevant?
Review
2002
Review
2002
Reviparin sodium (Clivarine), Knoll AG) is a low molecular weight heparin (LMWH) with a mean peak molecular weight of 3900 Da. It… (More)
Is this relevant?
2001
2001
PURPOSE Deep venous thrombosis (DVT) is a common, important complication of major orthopaedic surgery, particularly knee… (More)
Is this relevant?
2001
2001
Previous studies in rats show that unfractionated heparin and the low molecular weight heparin logiparin have a dose-dependent… (More)
Is this relevant?
Review
2001
Review
2001
UNLABELLED Reviparin (reviparin sodium) is a low molecular weight heparin (LMWH) that catalyses the inactivation of factors Xa… (More)
Is this relevant?
1997
1997
A prospective, randomised, controlled clinical trial was carried out in order to elucidate the incidence of venous… (More)
Is this relevant?
1997
1997
BACKGROUND Low-molecular-weight heparin is known to be safe and effective for the initial treatment of patients with proximal… (More)
Is this relevant?
1997
1997
A prospective, randomised, controlled clinical trial was carried out in order to elucidate the incidence of venous… (More)
Is this relevant?
Review
1996
Review
1996
Use of low molecular weight heparins (LMWHs) is now generally accepted as an ideal method of prophylaxis against postoperative… (More)
Is this relevant?